Literature DB >> 22763871

Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma.

Stanley Park1, Chi-Chao Chan.   

Abstract

Von Hippel-Lindau (VHL) disease is a highly penetrant autosomal dominant systemic malignancy that gives rise to cystic and highly vascularized tumors in a constellation of organs. Patients with VHL disease commonly present with hemangioblastomas in the central nervous system and the eye while other manifestations include pheochromocytoma, clear cell renal cell carcinoma, endolymphatic sac tumors of the middle ear, pancreatic cystadenomas, epididymal and broad ligament cystadenomas. Animal models inactivating the VHL gene product in various organ tissues have been constructed over the past 15 years to parse its HIF-associated mechanisms and its link to tumorigenesis. These models, despite advancing our understanding the molecular role of VHL, are by and large unable to recapitulate the more common features of human VHL disease. Up to date, no model exists that develop retinal hemangioblastomas, the most common clinical manifestation. The purpose of this review is: (1) to discuss the need for an ocular VHL model, (2) to review the animal models that recapitulate clinical VHL disease and (3) to propose potential mechanisms of tumorigenesis for the development of ocular VHL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22763871      PMCID: PMC3407271          DOI: 10.14670/HH-27.975

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  109 in total

1.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Authors:  Sonny O Ang; Hua Chen; Kiichi Hirota; Victor R Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I Sergueeva; Galina Y Miasnikova; David Mole; Patrick H Maxwell; David W Stockton; Gregg L Semenza; Josef T Prchal
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

2.  Genotype-phenotype correlation in ocular von Hippel-Lindau (VHL) disease: the effect of missense mutation position on ocular VHL phenotype.

Authors:  Pradeep Mettu; Elvira Agrón; Sonia Samtani; Emily Y Chew; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

3.  Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinoma.

Authors:  Jianming Pei; Madelyn M Feder; Tahseen Al-Saleem; Zemin Liu; Angen Liu; Gary R Hudes; Robert G Uzzo; Joseph R Testa
Journal:  Genes Chromosomes Cancer       Date:  2010-07       Impact factor: 5.006

4.  Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

Authors:  V H Haase; J N Glickman; M Socolovsky; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

5.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Authors:  Xiaoling Liang; Defen Shen; Yongsheng Huang; Chunyue Yin; Christine M Bojanowski; Zhengping Zhuang; Chi-Chao Chan
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

6.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

Review 7.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

8.  Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1alpha.

Authors:  Denise A Chan; Patrick D Sutphin; Nicholas C Denko; Amato J Giaccia
Journal:  J Biol Chem       Date:  2002-08-16       Impact factor: 5.157

9.  Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

Authors:  Michael Zimmer; Darrell Doucette; Naila Siddiqui; Othon Iliopoulos
Journal:  Mol Cancer Res       Date:  2004-02       Impact factor: 5.852

10.  VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.

Authors:  C M Lee; M M Hickey; C A Sanford; C G McGuire; C L Cowey; M C Simon; W K Rathmell
Journal:  Oncogene       Date:  2009-03-02       Impact factor: 9.867

View more
  4 in total

1.  Rb1/Rbl1/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma.

Authors:  Ran Wei; Xiang Ren; Hongyu Kong; Zhongping Lv; Yongjiang Chen; Yunjing Tang; Yujiao Wang; Lirong Xiao; Tao Yu; Sabiha Hacibekiroglu; Chen Liang; Andras Nagy; Rod Bremner; Danian Chen
Journal:  JCI Insight       Date:  2019-11-14

2.  Deletion of the von Hippel-Lindau Gene in Hemangioblasts Causes Hemangioblastoma-like Lesions in Murine Retina.

Authors:  Herui Wang; Matthew J Shepard; Chao Zhang; Lijin Dong; Dyvon Walker; Liliana Guedez; Stanley Park; Yujuan Wang; Shida Chen; Ying Pang; Qi Zhang; Chun Gao; Wai T Wong; Henry Wiley; Karel Pacak; Emily Y Chew; Zhengping Zhuang; Chi-Chao Chan
Journal:  Cancer Res       Date:  2018-01-04       Impact factor: 12.701

3.  Neuroprotective effects respond to cerebral ischemia without susceptibility to HB-tumorigenesis in VHL heterozygous knockout mice.

Authors:  Ying Wang; Jingyun Yang; Guhong Du; Dexuan Ma; Liangfu Zhou
Journal:  Mol Carcinog       Date:  2017-06-30       Impact factor: 4.784

4.  Hemangioblast: origin of hemangioblastoma in von Hippel-Lindau (VHL) syndrome.

Authors:  Herui Wang; Zhengping Zhuang; Chi-Chao Chan
Journal:  Oncoscience       Date:  2018-08-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.